SPC
ROIV icon

Slate Path Capital’s Roivant Sciences ROIV Stock Holding History

Slate Path Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,460,000
Closed -$27.6M – 75
2023
Q4 		$27.6M Buy
+2,460,000
New +$24M 0.61% 38

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Slate Path Capital's ROIV Position: Q1 2024 in Review

Slate Path Capital sold out of Roivant Sciences (ROIV) in Q1 2024, closing a stake of 2,460,000 shares — an estimated $27.6M sold.

Slate Path Capital first reported a position in ROIV in Q4 2023 and held it in 1 quarter. The position peaked at $27.6M in Q4 2023. 259 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

  • Slate Path Capital reported no remaining Roivant Sciences position as of Q1 2024 after selling out during the quarter.
  • Slate Path Capital sold 2,460,000 Roivant Sciences shares in Q1 2024, an estimated $27.6M.
  • Slate Path Capital first reported a position in Roivant Sciences in Q4 2023 and held it in 1 quarter.
  • Slate Path Capital's Roivant Sciences position peaked at $27.6M in Q4 2023.
  • 259 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on Slate Path Capital's 13F filing for Q1 2024, filed 15 May 2024.